VV-261

N/A

Report date: 2026/05/08 10:00:36
NME

Base Information

Drug NameVV-261
Drug Alias NameVV261VV-261
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRNA-directed RNA polymerase inhibitors
TargetsRNA-directed RNA polymerase
Therapy Area/IndicationsThrombocytopeniaChikungunya Fever
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesSuzhou Vigonvita Life Sciences Co LtdWuhan Institute Of Virology, Chinese Academy Of Sciences +[4] 
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuhan Institute Of Virology, Chinese Academy Of SciencesWangshan Wangshui (Shanghai) Biomedicine Co LtdSuzhou Vigonvita Life Sciences Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsThrombocytopeniaChikungunya Fever
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A